Navigation Links
Sales of Stem Cell Products Expected to Reach $87 Million in 2008, Leading Medical Industry Analyst Says
Date:2/1/2008

Robin R. Young to Provide 10-Year Forecast at 3rd Annual Stem Cell Summit

on Feb. 26

PHILADELPHIA, Feb. 1 /PRNewswire/ -- Stem cell product sales in the United States totaled $36 million in 2007, a 119 percent increase from the previous year, and are expected to reach $87 million, a 144 percent increase, in 2008, according to Robin R. Young, CFA, a medical industry analyst ranked as one of The Wall Street Journal's "Best on the Street" and among Institutional Investor's top-10.

The projections are based on Young's analysis of adult and human embryonic stem cell products currently sold or in development for the orthopedics, cardiovascular, anti-inflammatory, diabetes, nerve repair and dental markets.

"In recent months we've seen the largest stem cell product purchases in this fast-growing industry," Young said. "Physicians have already treated several thousands of patients in the United States with stem cell products. Moreover, the results of the clinical trials involving these types of products have been very impressive. This is a transformational year with the first-ever human embryonic stem cell products expected to enter the clinic."

Young will provide additional market data at the 3rd Annual Stem Cell Summit, which will take place Feb. 26 in New York City. The meeting is slated to be the largest gathering of stem cell company executives, scientists, investors and physicians. Attendees will learn about the investment opportunities in the stem cell marketplace, the groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. More information, including attendee registration details, is available at http://www.stemcellsummit.com.

Young has more than 25 years of experience as an analyst. He is the president of RRY Publications and the organizer of the Stem Cell Summit.

Contacts: Wendy Lau

Russo Partners, LLC

212-845-4272

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE RRY Publications
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
2. Mark Ostrowski Joins GenVault as Vice President of Sales and Marketing
3. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
4. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
5. /CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
8. ForceLogix, Innovex Win Sales Operational Performance Award
9. Southern Research Expands Sales and Marketing Agreement with Absorption Systems to Service European Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):